Case Report

Advanced Epithelioid Malignant Peripheral Nerve Sheath Tumor Showing Complete Response to Combined Surgery and Chemotherapy: A Case Report

Tomohiro Minagawa,1 Ryuta Shioya,2 Chigusa Sato,2 Ryuji Shichinohe,1 Go Yasui,1 Kohsuke Ishikawa,2 and Hiroko Takahashi1

1 Department of Plastic and Reconstructive Surgery, Asahikawa-Kosei General Hospital, 1 Jo-dohri 24-chome 111, Asahikawa City, Hokkaido 078-8211, Japan
2 Department of Plastic and Reconstructive Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido 060-0815, Japan

Correspondence should be addressed to Tomohiro Minagawa, tomhrmin@mountain.ocn.ne.jp

Received 23 May 2011; Accepted 6 July 2011

1. Introduction

Malignant peripheral nerve sheath tumor (MPNST) is a rare high-grade soft tissue sarcoma. Its variants include rhabdomyoblastic, glandular, and epithelioid MPNST [1]. Epithelioid MPNST (EMPNST) accounts for 5% or less of MPNSTs [1]. Approximately 40 cases of EMPNST have been reported in the English literature [2–5]. Most reports address clinicopathological features rather than therapeutic procedures or clinical courses. We describe a case of a 62-year-old male with an epithelioid MPNST of the left foot. Multiple lung metastases developed after radical surgery on the primary lesion. The response to adjuvant chemotherapy including doxorubicin and ifosfamide was favorable, and thoracoscopic resection was subsequently performed on the remaining three metastases. No evidence of recurrence or metastasis was observed at the 12-month followup after the first operation. Further followup and chemotherapy may be required.

2. Case Presentation

A 62-year-old male without neurofibromatosis presented with an enlarging, painful mass in the third web space of his left foot. The lesion was first noticed approximately five years earlier as a nodular lesion that was then diagnosed as an epidermal cyst of the sole at a dermatologic clinic. Neither excision nor biopsy was performed at that time. On examination, there was a firm, round mass measuring 9 × 7 cm in the third web space (Figure 1). The mass was immobile against the surrounding bones and adhered to the overlying skin. Multiple swollen lymph nodes were palpable in the left inguinal region. An open biopsy was performed, which showed proliferation of epithelioid round cells with cellular atypia, indicating probable malignant melanoma. Radiological examination including fluorodeoxyglucose positron emission tomography showed no evidence of definite distant metastases except left inguinal region (Figures 2(a) and 2(b)). Therefore, surgical treatment was planned under the diagnosis of T4aN2bM0, stage III-C malignant melanoma according to the American Joint Committee on Cancer classification.
The first operation was performed under general anesthesia. Left inguinal dissection was carried out (Figure 3(a)), and an adequately wide excision of the primary tumor with a 30 mm surgical margin (i.e., transmetatarsal amputation) was performed (Figure 3(b)). The resultant raw surface of the stump was temporarily covered with an artificial dermis. One week postoperatively, the stump was resurfaced with a free latissimus dorsi musculocutaneous flap with a split-thickness skin graft following histological confirmation of adequate surgical margins (Figure 3(c)). Although partial necrosis of the flap was observed postoperatively, application of an additional split-thickness skin graft under local anesthesia led to complete wound healing. The specimen showed nodular growth of the lesion measuring $70 \times 43$ mm between the dermis and subcutaneous layer without continuity to the epidermis. Histologically, the lesion consisted of two components: proliferation of spindle cells with some differentiation to nerve cells, reminiscent of conventional malignant schwannoma (Figure 4(a)), and epithelioid proliferation of round-to-polygonal or rhabdoid cells with hyperchromatic nuclei, reminiscent of malignant melanoma (Figures 4(b) and 4(c)). Tumor cells stained positive for S-100 protein and negative for HMB45 (Figure 4(d)). All dissected lymph nodes were free of sarcoma. Based on these histological features, the lesion was diagnosed as EMPNST, of which histological grade was classified as grade 3 according to the FNCLCC system (tumor differentiation: score 3, mitotic count: score 2, and tumor necrosis: score 1).

Ten weeks after the first operation, computed tomography demonstrated the development of multiple small bilateral lung nodules (Figures 5(a) and 5(b)). No further evidence of metastasis to other organs was observed. Systemic adjuvant chemotherapy consisting of doxorubicin and ifosfamide was then initiated. Doxorubicin (60 mg/m²) and ifosfamide (7.5 g/m²) with mesna (Uromitexan) were admin-
courses of adjuvant chemotherapy and a thoracic surgery were added, no signs of local recurrence or metastasis were observed (Figures 7(a) and 7(b)). The patient maintained ambulation without a brace (Figure 8).

3. Discussion

Most MPNSTs are generally considered high-grade sarcomas [1]. Approximately 40% of patients developed local recurrence, and the overall five-year survival rate was 34–43% [6, 7]. On the other hand, epithelioid variants are rare and are estimated to comprise 5% or fewer of MPNSTs [1]. Thus, biologic behavior and prognosis are unclear. However, the largest series, which included 26 cases and was reported by Laskin et al. [3], showed that although most patients were treated with wide excision, four developed distant metastases and three died of the disease within three years. High incidence of metastasis (seven of 14 cases) was also reported by Lodding et al. in 1986 [2].
Aggressive surgery is considered the only procedure to improve prognosis of the MPNST [6, 7], and the response to chemotherapy against MPNST is poor according to previous reports [8]; however, several reports have demonstrated that chemotherapy can be effective [9, 10]. Although the standard regimens are still investigative, ifosfamide and doxorubicin are considered key drugs for advanced soft tissue sarcomas [11, 12]. In our clinical case, administering ifosfamide and doxorubicin with mesna showed good efficacy on the multiple lung metastases, with low-grade toxicities including myelosuppression and hair loss.

Surgical management of lung metastases may be effective in select situations [13]. Two reports on MPNST demonstrated poor survival rates after development of pulmonary metastases; however, prolonged survived cases with thoracotomy were also described [7, 8]. As for nonosteogenic sarcoma, Creagan showed the overall 5-year survival following the first thoracotomy was 29% with a median survival of 18 months [14]. The present case involved the development of disseminating lung nodules ten weeks postoperatively; however, chemotherapy provided a favorable response to all metastatic lesions. Subsequently, thoracoscopic resection of the remaining three lesions was performed to both eliminate the sarcoma and allow histological evaluation of the response to chemotherapy. Based on the histological findings that two of the three lesions showed remaining
sarcoma, continuing the same regimen without surgery may risk inducing development of chemotherapy-resistant sarcoma cells.

4. Conclusions

An extremely rare case of advanced EMPNST was reported. Multiple metastases to both lungs developed despite the adequately wide excision of the primary tumor. However, adjuvant chemotherapy and thoracoscopic resection yielded a favorable and complete response at the 12-month followup.

Conflict of Interests

The authors declare that they have no competing interests.

Acknowledgments

The authors appreciate the advice and expertise of Drs. Kensuke Oikawa and Koji Sakurai, pathologists at Asahikawa Kosei General Hospital. Gratitude is also expressed to the Departments of Pathology and Dermatology of Asahikawa Medical College for advice on histological diagnoses. They also thank Dr. Tetsuo Funai for performing thoracic surgery.

References

[1] S. W. Weiss and J. R. Goldblum, “Malignant tumors of the peripheral nerves,” in Enzinger and Weiss’s Soft Tissue Tumors, S. W. Weiss and J. R. Goldblum, Eds., pp. 903–944, Mosby Elsevier, Philadelphia, Pa, USA, 5th edition, 2008.
[2] P. Lodding, L. G. Kindblom, and L. Angervall, “Epithelioid malignant schwannoma. A study of 14 cases,” Virchows Archiv, vol. 409, no. 4, pp. 433–451, 1986.
[3] W. B. Laskin, S. W. Weiss, and G. L. Bratthauer, “Epithelioid variant of malignant peripheral nerve sheath tumor (malignant epithelioid schwannoma),” American Journal of Surgical Pathology, vol. 15, no. 12, pp. 1136–1145, 1991.
[4] A. M. Manganoni, C. Farisoglio, A. Lonati, F. Zorzi, G. Tucci, and P. G. C. Pinton, “Cutaneous epithelioid malignant schwannoma: review of the literature and case report,” Journal of Plastic, Reconstructive and Aesthetic Surgery, vol. 62, no. 9, pp. e318–e321, 2009.
[5] S. Suster, K. Amazon, L. B. Rosen, and J. M. Ollague, “Malignant epithelioid schwannoma of the skin. A low-grade neurotropic malignant melanoma?” American Journal of Dermatopathology, vol. 11, no. 4, pp. 338–344, 1989.
[6] B. S. Ducatman, B. W. Scheithauer, and D. G. Piepgras, “Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases,” Cancer, vol. 57, no. 10, pp. 2006–2021, 1986.
[7] J. E. Wanebo, J. M. Malik, S. R. VandenBerg, H. J. Wanebo, N. Driesen, and J. A. Persing, “Malignant peripheral nerve sheath tumors: a clinicopathologic study of 28 cases,” Cancer, vol. 71, no. 4, pp. 1247–1253, 1993.
[8] P. P. Sordillo, L. Nelson, S. I. Hajdu et al., “Malignant schwannoma—clinical characteristics, survival, and response to therapy,” Cancer, vol. 47, no. 10, pp. 2503–2509, 1981.
[9] E. Zambrana, D. Vicente, T. Garcia-Manrique, S. Pereira, J. S. Zaitguy, and L. D. L. C. Merino, “Primary intracranial malignant peripheral nerve sheath tumour responding to chemotherapy,” Clinical and Translational Oncology, vol. 12, no. 3, pp. 231–233, 2010.
[10] F. Masui, R. Yokoyama, S. Soshi, Y. Beppu, K. Asanuma, and K. Fujii, “A malignant peripheral nerve-sheath tumour responding to chemotherapy,” Journal of Bone and Joint Surgery B, vol. 86, no. 1, pp. 113–115, 2004.
[11] J. H. Edmonson, L. M. Ryan, R. H. Blum et al., “Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas,” Journal of Clinical Oncology, vol. 11, no. 7, pp. 1269–1275, 1993.
[12] T. Goto, T. Okuma, K. Ogura, J. Imanishi, T. Hozumi, and T. Kondo, “Indication of chemotherapy according to histological type of musculoskeletal sarcomas,” Japanese Journal of Cancer and Chemotherapy, vol. 36, no. 2, pp. 199–203, 2009.
[13] J. A. Roth, J. B. Putnam, M. N. Wesley, and S. A. Rosenberg, “Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients,” Cancer, vol. 55, no. 6, pp. 1361–1366, 1985.
[14] E. T. Creagan, T. R. Fleming, J. H. Edmonson, and P. C. Pairolero, “Pulmonary resection for metastatic nonosteogenic sarcoma,” Cancer, vol. 44, no. 5, pp. 1908–1912, 1979.